Selected article for: "acute addition respiratory syndrome and addition respiratory syndrome"
Author: Massoomi, Michael R.; Anderson, R. David; Ahmed, Mustafa M.; Dasa, Osama; George, Philip; Miles, William M.; Aranda, Juan M.; Pepine, Carl J.
Title: Cardiovascular Considerations for the Internist and Hospitalist in the COVID-19 Era
  • Cord-id: bpzwx27u
  • Document date: 2020_7_10
    • ID: bpzwx27u
    Snippet: It is clear that existing cardiovascular disease is a major risk factor for COVID-19 and related adverse outcomes. In addition to acute respiratory syndrome, a large cohort also develop myocardial and/or vascular dysfunction, in part from inflammation and renin angiotensin system activation with increased sympathetic outflow, cardiac arrhythmias, ischemia, heart failure, and thromboembolic complications that portend poor COVID-19 outcomes. We summarize here recent information for hospitalists/in
    Document: It is clear that existing cardiovascular disease is a major risk factor for COVID-19 and related adverse outcomes. In addition to acute respiratory syndrome, a large cohort also develop myocardial and/or vascular dysfunction, in part from inflammation and renin angiotensin system activation with increased sympathetic outflow, cardiac arrhythmias, ischemia, heart failure, and thromboembolic complications that portend poor COVID-19 outcomes. We summarize here recent information for hospitalists/internists on the front-line of this pandemic regarding its cardiovascular impacts and management and need for cardiovascular consultation.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and acute coronary syndrome: 1
    • ace inhibitor and acute myocardial infarction: 1, 2
    • ace inhibitor and acute myocardial injury: 1
    • ace inhibitor and low molecular weight: 1
    • ace inhibitor and low molecular weight heparin: 1
    • ace inhibitor and lung injury: 1, 2, 3, 4
    • acei ace inhibitor and lung injury: 1, 2
    • acute cardiomyopathy and admission qtc: 1
    • acute cardiomyopathy and low molecular weight: 1
    • acute cardiomyopathy and low molecular weight heparin: 1
    • acute cardiomyopathy and lung injury: 1
    • acute care and low molecular weight: 1, 2, 3, 4
    • acute care and low molecular weight heparin: 1, 2, 3, 4
    • acute care and low risk patient: 1
    • acute care and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
    • acute care need and lung injury: 1